ArticleCureus2025
Cardiac Kaposi Sarcoma Complicated by Kaposi Sarcoma Inflammatory Cytokine Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Kaposi sarcoma (KS), caused by human herpesvirus-8 (HHV-8), is among the most common malignancies in people living with HIV. Kaposi sarcoma is an angiogenic endothelial cell neoplasm and an acquired immunodeficiency syndrome (AIDS)-defining illness. Kaposi sarcoma is associated with high mortality when presenting as visceral or disseminated disease or when complicated by Kaposi sarcoma inflammatory cytokine syndrome (KICS), immune reconstitution inflammatory syndrome, or multicentric Castleman disease. We present the case of a 26-year-old male patient found to have AIDS-related KS complicated by cardiac, pulmonary, gastrointestinal, and skin involvement as well as KICS. Notably, the patient's skin lesions were not identified at the initial hospital presentation. He was treated with doxorubicin for KS and rituximab for KICS but died shortly after KICS diagnosis. We highlight the importance of recognizing KS skin lesions to aid in early diagnosis and of recognizing signs and symptoms of KICS to expedite immunomodulatory therapy initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.